Advances in the research and development of new drugs for chronic hepatitis B
10.3969/j.issn.1001-5256.2022.06.035
- VernacularTitle:治疗慢性乙型肝炎新药研发的研究进展
- Author:
Yisi LIU
1
;
Xinyue CHEN
1
Author Information
1. First Department of Liver Disease Center, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
- Publication Type:Reviews
- Keywords:
Hepatitis B, Chronic;
Drug Discovery;
Clinical Trial
- From:
Journal of Clinical Hepatology
2022;38(6):1387-1392
- CountryChina
- Language:Chinese
-
Abstract:
At present, antiviral therapy for chronic hepatitis B (CHB) has a low clinical cure rate and hardly remove cccDNA. With the progress of medical science, more and more new drugs are in the stage of research and development. This article focuses on the research and development of representative drugs with relatively detailed clinical trial data. Rapid progress has been made in the new drugs such as small-interfering RNA and core protein allosteric modulators in recent years. The results of clinical trials show that it still takes some time for new drugs to enter clinical use, and multi-drug combination therapy may become the trend of treatment in the future.
